Skip to content

epoc NXS Host 11413475

by Epocal Inc

epoc NXS Host 11413475 (16266) is a metabolic profile clinical chemistry analyser IVD (FDA Class I) made by Epocal Inc, cleared under FDA 510(k) K200107 on 5 Jun 2020 and listed in FDA GUDID since 18 Jun 2020 (UDI-DI 00630414606095), active as of 23 Oct 2026. 19 FDA recalls are linked to it.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

18 ongoing

This device is named in the recall

Documents

510(k) K200107

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 23 Oct 2026.

Regulatory status

as of registry sync 23 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number00630414606095 UDI-DI Date18 Jun 2020ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE from GUDID Substantially Equivalent · Special NumberK200107 Date5 Jun 2020DecidedStatusActive

Official records

From the FDA record

Device description
The epoc Blood Analysis System, is intended for use by trained medical professionals as an in vitro diagnostic device for thequantitative testing of samples of heparinized or un-anticoagulated arterial, venous or capillary whole blood in the laboratoryor at the point of care in hospitals, nursing homes or other clinical care institutions.
MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 23 Oct 2026, as the labeller entered it.

Across registries

2 registries list this device

  • FDA 510(k) K200107 decided 5 Jun 2020 Active
  • FDA GUDID UDI-DI 00630414606095 listed 18 Jun 2020 Listed

Recalls

19 recalls · 18 ongoing · FDA

    • Ongoing Z-2005-2026 FDA Class II initiated 2 Apr 2026

    Use of the affected product can result in discrepant low pH and measured Total Carbon Dioxide (mTCO2) results and corresponding calculated values in arterial, venous, and capillary patient samples. An erroneously low pH or mTCO2 reading can lead to inappropriate treatment of nonexistent acidosis (respiratory of metabolic) or missed diagnosis of alkalosis (a true high pH: respiratory or metabolic alkalosis), potentially causing harm through unnecessary interventions with the former or failure to deliver appropriate treatment with the latter.

    • Ongoing Z-2272-2025 FDA Class II initiated 7 Jul 2025

    Siemens Healthcare Diagnostics Inc. has confirmed that a negative sodium bias may exist in some epoc test card lots. All other analytes are performing as intended. The observed average bias for sodium was -4.4 mmol/L. The maximum bias observed was -14 mmol/L, which occurred at a higher sodium concentration around 150 mmol/L. No positive bias has been observed. Quality Control (QC) fluid may or may not detect the issue depending on the bias magnitude and the frequency of QC testing.

  • 2 recalls, same reason

    • Ongoing Z-1685-2025 FDA Class II initiated 19 Mar 2025
    • Ongoing Z-1684-2025 FDA Class II initiated 19 Mar 2025

    The occurrence of discrepant high pH results in samples introduced with higher injection volumes with epoc sensor configuration 45.n.

  • 8 recalls, same reason

    • Ongoing Z-0741-2025 FDA Class II initiated 22 Nov 2024
    • Ongoing Z-0735-2025 FDA Class II initiated 22 Nov 2024
    • Ongoing Z-0739-2025 FDA Class II initiated 22 Nov 2024
    • Ongoing Z-0740-2025 FDA Class II initiated 22 Nov 2024
    • Ongoing Z-0734-2025 FDA Class II initiated 22 Nov 2024
    • Ongoing Z-0736-2025 FDA Class II initiated 22 Nov 2024
    • Ongoing Z-0738-2025 FDA Class II initiated 22 Nov 2024
    • Ongoing Z-0737-2025 FDA Class II initiated 22 Nov 2024

    Siemens Healthcare Diagnostics is recalling their epoc Blood Analysis System because of a software malfunction that occurs when specific criteria are met that can result in the incorrect patient name being assigned to a blood measurement by the device if the user of the device does not ensure verification of the correct patient name. The software malfunction has the potential to impact patient safety via misdiagnosis and/or mistreatment by a clinician if the wrong patient information is saved with the test result from the subject device.

    • Ongoing Z-0286-2025 FDA Class II initiated 24 Sep 2024

    Siemens Healthcare Diagnostics Inc. has confirmed that a negative sodium bias may exist in one lot of epoc BGEM BUN Test Cards approximately 2 months prior to expiration. The observed maximum negative bias from internal testing is -10 mmol/L. No positive bias has been observed. Quality Control (QC) fluid may or may not detect the issue depending on the bias magnitude and the frequency of QC testing. One customer complaint has been associated with this issue. No adverse events have been reported. All affected lots have recently expired before the issuance of the recall.

    • Ongoing Z-0601-2024 FDA Class II initiated 19 Oct 2023

    Siemens Healthcare Diagnostics Inc. has confirmed a potential issue that could occur under certain conditions, a software problem is causing erroneous results to be printed. When the results are run on the epoc NXS Host and Delete Blood Tests feature is enabled, the results that are generated at the time of testing are correct; however, when this issue occurs, results that are printed, saved and/or transferred to a data manager, may include unselected analytes that are from a previous patient or QC test. The worst possible outcome may result in a failure to diagnose hyperkalemia, due to an erroneous depressed potassium level or inappropriate treatment to hyperglycemia due to erroneous glucose reading.

  • 3 recalls, same reason

    • Ongoing Z-2477-2023 FDA Class II initiated 1 Jun 2023
    • Ongoing Z-2476-2023 FDA Class II initiated 1 Jun 2023
    • Ongoing Z-2478-2023 FDA Class II initiated 1 Jun 2023

    There is potential for discrepant high glucose results in samples with glucose results on the lower end of the reportable range.

    • Ongoing Z-1215-2023 FDA Class II initiated 12 Dec 2022

    pO2 High Recovery in Quality Control When Adjusted for Barometric Pressure

    • Terminated Z-2970-2020 FDA Class II initiated 28 Aug 2020

    Sporadically inconsistent discrepant (low bias) glucose results on card lot 01-20095-10. Potential exists for a delay in diagnosis of hyperglycemia or unnecessary treatment for hypoglycemia.

Timeline

21 dated events

  1. Recall initiated FDA recalls Z-0739-2025
  2. Recall initiated FDA recalls Z-0740-2025
  3. Recall initiated FDA recalls Z-0734-2025
  4. Recall initiated FDA recalls Z-0736-2025
  5. Recall initiated FDA recalls Z-0738-2025
  6. Recall initiated FDA recalls Z-0737-2025
  7. Recall initiated FDA recalls Z-1685-2025
  8. Recall initiated FDA recalls Z-1684-2025
  9. Recall initiated FDA recalls Z-2272-2025
  10. Recall initiated FDA recalls Z-2005-2026

11 earlier events are in the sections above.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

GUDID

Trade name
epoc NXS Host
Generic name
Metabolic profile clinical chemistry analyser IVD
Model / Ref / Catalog
11413475, 16266
Primary DI / UDI-DI
00630414606095
510(k) Number
FDA product code
KHP, CEM, CGZ, JGS, JFP, CHL, JFL, CGA
GMDN term
Metabolic profile clinical chemistry analyser IVD
Device class
Class I
Regulation number
862.1450, 862.1600, 862.1170, 862.1665, 862.1145, 862.1120, 862.1160, 862.1345
GUDID distribution status
In Commercial Distribution

Similar devices in this category

Other devices filed under Metabolic profile clinical chemistry analyser IVD.

Other devices from Epocal Inc

See all devices from Epocal Inc →

Properties

  • Prescription use
  • Serial number
  • Manufacturing date
Other properties (12, all answered No)